



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

SCHWEIGHOFFER et al. Atty. Ref.: 3665-152; Confirmation No.

Appl. No. 10/541,503 TC/A.U. To be assigned

Filed: July 7, 2005 Examiner: To be assigned

For: METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATIVE  
OCULAR PATHOLOGIES

\* \* \* \* \*

April 2, 2009

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE**

Responsive to the Official Action dated March 3, 2009, the applicants elect the subject matter of the Examiner's Group I for further prosecution in the above.

The applicants elect, for the purpose of initial examination and without prejudice, Etazolate, as a PDE4 inhibitor, and Age-Related Macular Degeneration (ARMD), as an ocular disease. Claims 21-26, 29-31, 33 and 36, of the elected Group read on the elected species.

An early and favorable Action on the merits of the claimed invention is requested.

SCHWEIGHOFFER et al.

Appl. No. 10/541,503

Atty. Ref.: 3665-152

Response

April 2, 2009

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_ /B. J. Sadoff/  
\_\_\_\_\_  
B. J. Sadoff  
Reg. No. 36,663

BJS:

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000

Facsimile: (703) 816-4100